About FDC Limited

Founded in 1940, FDC Limited is an Indian pharmaceutical company engaged in manufacturing and marketing of pharmaceutical formulations and bulk drugs, with operations managed from India and exports to the USA and other international markets as part of a single reportable segment under Ind AS 108. As of March 31, 2025, the company operates 9 plants and 22 offices in India, plus 2 international offices, reflecting a total footprint of 33 locations globally. The group structure includes three foreign subsidiaries—FDC International Limited, FDC Inc., and Fair Deal Corporation Pharmaceuticals SA Pty Ltd.—with no material subsidiary designated by the board; consolidated net assets are predominantly in the parent at 98.76% as of March 31, 2025. Registered in Waluj, Aurangabad, with a corporate office in Andheri West, Mumbai, the company’s shares are listed on BSE and NSE under ISIN INE258B01022. Key corporate policies, governance practices, and internal control systems align with SEBI Listing Regulations, with unmodified statutory audit opinion for FY 2024–25.

FDC Limited Business Segment

• Operating model: Single business segment—pharmaceuticals—per Ind AS 108; performance monitored on revenue and gross profit by the CODM.
  

• Geography revenue split FY 2024–25:
  • India — Rs 1,788.65 crore (84.8%)

  • International — Rs 319.47 crore (15.2%)

  • USA within international — Rs 63.75 crore (3.0%)

FDC Limited Key Management

• Mohan A. Chandavarkar — Managing Director

• Nandan M. Chandavarkar — Joint Managing Director

• Ashok A. Chandavarkar — Executive Director

• Ameya A. Chandavarkar — CEO–International Business and Executive Director

• Nomita R. Chandavarkar — Non-Executive Director (Non-Independent)

• CA. Uday Kumar Gurkar — Chairman, Non-Executive Independent Director

• Dr. Charuta Nityanath Mandke — Non-Executive Independent Director

Latest Updates on FDC Limited

• Appointment of Dr. Charuta Nityanath Mandke as Non-Executive Independent Director for five years effective August 7, 2024; shareholders approved on September 26, 2024.

• Completion of tenures: M.G. Parameswaran and Usha A. Chandrasekhar on May 9, 2024; CA. Swati S. Mayekar on September 5, 2024.

• FY 2024–25 interim dividend declared at Rs 5 per equity share on 16,28,10,084 shares; aggregate outflow Rs 81.41 crore.

• Statutory auditors issued an unmodified opinion for FY 2024–25; management clarified on SAP audit-trail setting at database level with internal controls deemed adequate.

• CSR spend in FY 2024–25: Rs 5.67 crore across education, healthcare, and others; no ongoing CSR projects at year-end.

• Segment disclosure reaffirmed single business segment; FY 2024–25 revenue from operations Rs 2,108.12 crore with India, USA, and Others as secondary geographies.